Veritas Pharma Stock EBITDA

VRTHF Stock  USD 0  0.00  0.00%   
Veritas Pharma fundamentals help investors to digest information that contributes to Veritas Pharma's financial success or failures. It also enables traders to predict the movement of Veritas Pink Sheet. The fundamental analysis module provides a way to measure Veritas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Veritas Pharma pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Veritas Pharma Company EBITDA Analysis

Veritas Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Veritas Pharma EBITDA

    
  (491.67 K)  
Most of Veritas Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Veritas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Veritas Pharma reported earnings before interest,tax, depreciation and amortization of (491,673). This is 100.06% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all United States stocks is 100.01% higher than that of the company.

Veritas EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veritas Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Veritas Pharma could also be used in its relative valuation, which is a method of valuing Veritas Pharma by comparing valuation metrics of similar companies.
Veritas Pharma is currently under evaluation in ebitda category among its peers.

Veritas Fundamentals

About Veritas Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Veritas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veritas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veritas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Veritas Pink Sheet

Veritas Pharma financial ratios help investors to determine whether Veritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Veritas with respect to the benefits of owning Veritas Pharma security.